Metabolism-based approaches for autosomal dominant polycystic kidney disease

被引:4
作者
Bakaj, Ivona [1 ]
Pocai, Alessandro [1 ]
机构
[1] Janssen Res & Dev, Cardiovasc & Metab, Spring House, PA 19002 USA
关键词
ADPKD (autosomal dominant polycystic kidney disease); tolvaptan; metabolic reprograming; therapeutic approaches; metabolism & obesity; GLP-1; glucagon; RENAL-FUNCTION; FLUID SECRETION; PROGRESSION; AMPK; INHIBITION; OVERWEIGHT; VOLUME; GROWTH; GLP-1; MOUSE;
D O I
10.3389/fmolb.2023.1126055
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Autosomal Dominant Polycystic Kidney Disease (ADPKD) leads to end stage kidney disease (ESKD) through the development and expansion of multiple cysts throughout the kidney parenchyma. An increase in cyclic adenosine monophosphate (cAMP) plays an important role in generating and maintaining fluid-filled cysts because cAMP activates protein kinase A (PKA) and stimulates epithelial chloride secretion through the cystic fibrosis transmembrane conductance regulator (CFTR). A vasopressin V2 receptor antagonist, Tolvaptan, was recently approved for the treatment of ADPKD patients at high risk of progression. However additional treatments are urgently needed due to the poor tolerability, the unfavorable safety profile, and the high cost of Tolvaptan. In ADPKD kidneys, alterations of multiple metabolic pathways termed metabolic reprogramming has been consistently reported to support the growth of rapidly proliferating cystic cells. Published data suggest that upregulated mTOR and c-Myc repress oxidative metabolism while enhancing glycolytic flux and lactic acid production. mTOR and c-Myc are activated by PKA/MEK/ERK signaling so it is possible that cAMPK/PKA signaling will be upstream regulators of metabolic reprogramming. Novel therapeutics opportunities targeting metabolic reprogramming may avoid or minimize the side effects that are dose limiting in the clinic and improve on the efficacy observed in human ADPKD with Tolvaptan.
引用
收藏
页数:9
相关论文
共 119 条
[51]   Suppression of Gαs Synthesis by Simvastatin Treatment of Vascular Endothelial Cells [J].
Kou, Ruqin ;
Shiroto, Takashi ;
Sartoretto, Juliano L. ;
Michel, Thomas .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (04) :2643-2651
[52]   PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression [J].
Lakhia, Ronak ;
Ramalingam, Harini ;
Chang, Chun-Mien ;
Cobo-Stark, Patricia ;
Biggers, Laurence ;
Flaten, Andrea ;
Alvarez, Jesus ;
Valencia, Tania ;
Wallace, Darren P. ;
Lee, Edmund C. ;
Patel, Vishal .
NATURE COMMUNICATIONS, 2022, 13 (01)
[53]   PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice [J].
Lakhia, Ronak ;
Yheskel, Matanel ;
Flaten, Andrea ;
Quittner-Strom, Ezekiel B. ;
Holland, William L. ;
Patel, Vishal .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2018, 314 (01) :F122-F131
[54]   Thiazolidinediones: the Forgotten Diabetes Medications [J].
Lebovitz, Harold E. .
CURRENT DIABETES REPORTS, 2019, 19 (12)
[55]   Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease [J].
Lee, Edmund C. ;
Valencia, Tania ;
Allerson, Charles ;
Schairer, Annelie ;
Flaten, Andrea ;
Yheskel, Matanel ;
Kersjes, Kara ;
Li, Jian ;
Gatto, Sole ;
Takhar, Mandeep ;
Lockton, Steven ;
Pavlicek, Adam ;
Kim, Michael ;
Chu, Tiffany ;
Soriano, Randy ;
Davis, Scott ;
Androsavich, John R. ;
Sarwary, Salma ;
Owen, Tate ;
Kaplan, Julia ;
Liu, Kai ;
Jang, Graham ;
Neben, Steven ;
Bentley, Philip ;
Wright, Timothy ;
Patel, Vishal .
NATURE COMMUNICATIONS, 2019, 10 (1)
[56]   ATP-citrate lyase regulates cellular senescence via an AMPK- and p53-dependent pathway [J].
Lee, Jong-Hyuk ;
Jang, Hyonchol ;
Lee, Soon-Min ;
Lee, Ji-Eun ;
Choi, Jinmi ;
Kim, Tae Wan ;
Cho, Eun-Jung ;
Youn, Hong-Duk .
FEBS JOURNAL, 2015, 282 (02) :361-371
[57]   Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease [J].
Leonhard, Wouter N. ;
Song, Xuewen ;
Kanhai, Anish A. ;
Iliuta, Ioan-Andrei ;
Bozovic, Andrea ;
Steinberg, Gregory R. ;
Peters, Dorien J. M. ;
Pei, York .
EBIOMEDICINE, 2019, 47 :436-445
[58]   The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease [J].
Lian, Xiaoying ;
Wu, Xiaoyuan ;
Li, Zhongxin ;
Zhang, Yingjie ;
Song, Kangkang ;
Cai, Guangyan ;
Li, Qinggang ;
Lin, Shupeng ;
Chen, Xiangmei ;
Bai, Xue-Yuan .
BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (05) :711-724
[59]   Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis [J].
Lin, Chun-Hung ;
Chao, Chia-Ter ;
Wu, Mei-Yi ;
Lo, Wei-Cheng ;
Lin, Tsu-Chen ;
Wu, Mai-Szu .
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (11) :2015-2025
[60]   The PI3K/Akt/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium [J].
Margaria, Jean Piero ;
Campa, Carlo Cosimo ;
De Santis, Maria Chiara ;
Hirsch, Emilio ;
Franco, Irene .
CELLULAR SIGNALLING, 2020, 66